The PENTO Protocol in Medication-related Osteonecrosis of the Jaw
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 17
- 试验地点
- 2
- 主要终点
- Exposure bone area (EBA)
研究概览
简要总结
Medication-related osteonecrosis of the jaw (MRONJ) occurs after taking bisphosphonates or targeted therapies. It leads to a significant decrease in quality of life with pain, eating and chewing disorders, and malnutrition. Current treatments are only partially effective. PENTO (pentoxifylline and tocopherol) has been shown to be effective in maxillary osteoradionecrosis. The objective of this study is to evaluate the proportion of bone recovery in patients receiving PENTO in MRONJ at 12 months.
详细描述
MRONJ is defined as intraoral bone exposure persisting for more than 8 weeks after taking an anti-resorptive agent (per os or IV bisphosphonates, targeted therapies) and without history of maxilla radiotherapy or metastasis. It leads to a significant decrease in quality of life with significant pain at rest and during mastication, and compromised nutrition, sometimes resulting in severe undernutrition in patients already weakened by a history of cancer. Current treatments (prolonged antibiotic therapy, repeated bone curettage) have shown partial effectiveness. PENTO (combination of pentoxifylline, a vasodilator, and tocopherol, vitamin E) has been shown to significantly reduce intraoral exposed bone surface area and pain in maxilla osteoradionecrosis. All studies conducted so far on PENTO in MRONJ are retrospective or involve small samples. Therefore, our idea is to perform a well-conducted prospective phase IIa study to prove the efficacy of PENTO, with a larger sample size and identical follow-up periods. The investigators will study patients with AAOMS stage 2 MRONJ (exposed bone in symptomatic patients, without pathologic fracture).
Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening. Antibiotic therapy with Augmentin (or clindamycin) will be added for the first month and then punctually if signs of local infection appear.
The primary and secondary endpoints will be assessed at inclusion and at 1, 3, 6 and 12 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age greater than or equal to 18 years
- •Current or past treatment with bisphosphonates (oral or IV) and/or targeted therapies (denosumab, bevacizumab)
- •Signs and symptoms for more than 8S with confirmation that the signs and symptoms are not of dental origin
- •AAOMS Stage 2 MRONJ
- •For patients of childbearing age, effective contraception is required
排除标准
- •History of head or neck radiotherapy or maxilla metastases
- •Patients who have received treatment in the past (PENTO or PENTOCLO protocol)
- •Patients who have undergone surgery for their MRONJ within the last 3 months
- •Pregnant or wishing to be pregnant, breastfeeding
- •Patient under palliative care
- •Patient with hypersensitivity to pentoxifylline or tocopherol or to an excipient
- •History of hypersensitivity reaction to penicillins, cephalosporins, or other beta-lactams (and clindamycin or lincomycin if applicable) or excipient of amoxicillin-a. clavulanic or clindamycin
- •History of jaundice/hepatic injury related to amoxicillin/clavulanic acid
- •Patient taking oral anticoagulants, or with a history of major bleeding or bleeding disorders
- •Patient taking platelet aggregation inhibitor, theophylline or aminophylline
- •Patient taking methotrexate, probenecid, mycophenolate mofetil, myorelaxant drugs, macrolide or streptogramin antibiotics
- •Patients with hepatic failure or renal failure (Cl < 30 mL/min),
- •Patient with hypotension (SBP < 90 mmHg)
- •Refusal to participate in the study
- •Patient participating in other interventional research that may interfere with the conduct of this research
- •Patient unable to understand the protocol
- •Patient under curatorship or guardianship
研究组 & 干预措施
Pentoxifylline
Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening
干预措施: Pentoxifylline+Tocopherol (Drug)
结局指标
主要结局
Exposure bone area (EBA)
时间窗: Month 12
exposure bone area (EBA) less than 5 mm at 12 months. It will be expressed as the percentage of patients who achieved healing (EBA \< 5 mm) at 12 months.
次要结局
- Nutritional parameters evolution (albuminemia)(Month 1, Month 3, Month 6, Month 12)
- Nutritional parameters evolution (pre-albuminemia)(Month 1, Month 3, Month 6, Month 12)
- Nutritional parameters evolution (weight)(Month 1, Month 3, Month 6, Month 12)
- SOMA score(Month 1, Month 3, Month 6, Month 12)
- Nutritional parameters evolution (BMI)(Month 1, Month 3, Month 6, Month 12)
- Exposure bone area (EBA)(Month 1, Month 3, Month 6, Month 12)
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])(Month 1, Month 3, Month 6, Month 12)